leflunomide has been researched along with Chronic Illness in 14 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The records were reviewed from all patients treated at a tertiary sarcoidosis center from July 2002-July 2003, and information from patients treated with either leflunomide or methotrexate was analyzed for efficacy and toxicity." | 9.11 | Leflunomide for chronic sarcoidosis. ( Baughman, RP; Lower, EE, 2004) |
| "To investigate the effect of leflunomide on the inflammatory factors and immune function of rats with chronic glomerulonephritis." | 7.83 | [Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis]. ( Deng, F; Feng, J; Wang, L; Zhang, P, 2016) |
| "Chronic anterior uveitis is a serious complication of juvenile idiopathic arthritis (JIA); disease flares are highly associated with loss of vision." | 5.42 | Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. ( Benseler, SM; Bichler, J; Haas, JP; Hügle, B; Krumrey-Langkammerer, M, 2015) |
| "Rheumatoid nodules are well established manifestations of rheumatoid arthritis but in the lungs they are very rare according to the literature." | 5.35 | Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide. ( Csiki, Z; Horvath, IF; Szanto, A; Szodoray, P; Zeher, M, 2008) |
| "The records were reviewed from all patients treated at a tertiary sarcoidosis center from July 2002-July 2003, and information from patients treated with either leflunomide or methotrexate was analyzed for efficacy and toxicity." | 5.11 | Leflunomide for chronic sarcoidosis. ( Baughman, RP; Lower, EE, 2004) |
| "A morning standard dose of 250 mcg tetracosactide (Synacthen test) was given in 25 consecutive patients (13 rheumatoid arthritis, 2 psoriatic arthritis, 5 systemic lupus erythematosus, 2 dermatomyositis, 1 systemic sclerosis, 2 temporal arteritis) at the time of relapse upon small reductions (1-2 mg daily) of low prednisolone dose (<7." | 4.12 | Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose. ( Filippa, MG; Panopoulos, S; Sfikakis, PP; Spanos, E; Spanos, G; Tektonidou, MG; Yavropoulou, MP, 2022) |
| "To investigate the effect of leflunomide on the inflammatory factors and immune function of rats with chronic glomerulonephritis." | 3.83 | [Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis]. ( Deng, F; Feng, J; Wang, L; Zhang, P, 2016) |
| "Leflunomide treatment was associated with significant gastrointestinal and other adverse effects leading 40% of patients to discontinue therapy." | 1.56 | Use of leflunomide in patients with chronic hypersensitivity pneumonitis. ( Culver, DA; Li, M; Noh, S; Pande, A; Sahoo, D; Wang, X; Yadav, R, 2020) |
| "Chronic anterior uveitis is a serious complication of juvenile idiopathic arthritis (JIA); disease flares are highly associated with loss of vision." | 1.42 | Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. ( Benseler, SM; Bichler, J; Haas, JP; Hügle, B; Krumrey-Langkammerer, M, 2015) |
| "Rheumatoid nodules are well established manifestations of rheumatoid arthritis but in the lungs they are very rare according to the literature." | 1.35 | Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide. ( Csiki, Z; Horvath, IF; Szanto, A; Szodoray, P; Zeher, M, 2008) |
| "Leflunomide is a drug used clinically in the treatment of rheumatoid arthritis." | 1.34 | Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells. ( Nakayamada, S; Ra, C; Saito, K; Sawamukai, N; Tanaka, Y; Yamaoka, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Yavropoulou, MP | 1 |
| Filippa, MG | 1 |
| Panopoulos, S | 1 |
| Spanos, E | 1 |
| Spanos, G | 1 |
| Tektonidou, MG | 1 |
| Sfikakis, PP | 1 |
| Wang, Y | 1 |
| Zhao, Z | 1 |
| Gao, D | 1 |
| Wang, H | 1 |
| Liao, S | 1 |
| Luo, G | 1 |
| Ji, X | 1 |
| Li, Y | 1 |
| Wang, X | 2 |
| Zhao, Y | 1 |
| Li, K | 1 |
| Zhang, J | 2 |
| Jin, J | 1 |
| Zhang, Y | 1 |
| Zhu, J | 1 |
| Huang, F | 1 |
| Noh, S | 1 |
| Yadav, R | 1 |
| Li, M | 1 |
| Sahoo, D | 1 |
| Culver, DA | 1 |
| Pande, A | 1 |
| Molina, C | 1 |
| Modesto, C | 1 |
| Martín-Begué, N | 1 |
| Arnal, C | 1 |
| Aletaha, D | 1 |
| Alasti, F | 1 |
| Smolen, JS | 1 |
| Bichler, J | 1 |
| Benseler, SM | 1 |
| Krumrey-Langkammerer, M | 1 |
| Haas, JP | 1 |
| Hügle, B | 1 |
| Deng, F | 1 |
| Zhang, P | 1 |
| Feng, J | 1 |
| Wang, L | 1 |
| Baughman, RP | 1 |
| Lower, EE | 1 |
| Sawamukai, N | 1 |
| Saito, K | 1 |
| Yamaoka, K | 1 |
| Nakayamada, S | 1 |
| Ra, C | 1 |
| Tanaka, Y | 1 |
| Horvath, IF | 1 |
| Szanto, A | 1 |
| Csiki, Z | 1 |
| Szodoray, P | 1 |
| Zeher, M | 1 |
| MacDonald, AS | 1 |
| Sabr, K | 1 |
| MacAuley, MA | 1 |
| McAlister, VC | 1 |
| Bitter-Suermann, H | 1 |
| Lee, T | 1 |
| Kurtz, ES | 1 |
| Bailey, SC | 1 |
| Arshad, F | 1 |
| Lee, AA | 1 |
| Przekop, PA | 1 |
| Shen, J | 1 |
| Chong, AS | 1 |
| Xiao, F | 1 |
| Liu, W | 1 |
| Huang, W | 1 |
| Blinder, L | 1 |
| Foster, P | 1 |
| Sankary, H | 1 |
| Jensik, S | 1 |
| McChesney, L | 1 |
| Mital, D | 1 |
| Williams, JW | 1 |
| Hoshi, K | 1 |
| Hiida, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Impaired Functional Reserve of Adrenal Cortex May Associate With difficult-to Treat RA: Can a Disturbed Cortisol Circadian Rhythm Serve as a Predictor of Difficult-to-treat RA?[NCT05671627] | 50 participants (Anticipated) | Observational | 2022-02-02 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for leflunomide and Chronic Illness
| Article | Year |
|---|---|
[Rheumatic pain].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheum | 2001 |
1 trial available for leflunomide and Chronic Illness
| Article | Year |
|---|---|
Leflunomide for chronic sarcoidosis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Drug Therapy, Combination; Fe | 2004 |
12 other studies available for leflunomide and Chronic Illness
| Article | Year |
|---|---|
Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenal Insufficiency; Antirheumatic Agents; Arthritis, Rhe | 2022 |
Clinical value of plasmablasts in predicting disease relapse in patients with IgG4-related disease.
Topics: Chronic Disease; Humans; Immunoglobulin G; Immunoglobulin G4-Related Disease; Leflunomide; Plasma Ce | 2023 |
Use of leflunomide in patients with chronic hypersensitivity pneumonitis.
Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Carbon Monoxide; Chronic Disease; Female; Humans; Immun | 2020 |
Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis.
Topics: Adolescent; Adult; Antirheumatic Agents; Arthritis, Juvenile; Child; Chronic Disease; Female; Humans | 2013 |
Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Ag | 2015 |
Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Child; Child, Preschool; Chronic Disease; Cohort Studies; | 2015 |
[Effect of Leflunomideon Inflammatory Factors and Immune Function in Rats with Chronic Glomerulonephritis].
Topics: Animals; Chronic Disease; Disease Models, Animal; Glomerulonephritis; Inflammation; Interleukin-6; I | 2016 |
Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
Topics: Aniline Compounds; Apoptosis; Arthritis, Rheumatoid; Cell Survival; Cells, Cultured; Chronic Disease | 2007 |
Intrapulmonary rheumatoid nodules in a patient with long-standing rheumatoid arthritis treated with leflunomide.
Topics: Adult; Arthritis, Rheumatoid; Chronic Disease; Female; Humans; Isoxazoles; Leflunomide; Lung Disease | 2008 |
Effects of leflunomide and cyclosporine on aortic allograft chronic rejection in the rat.
Topics: Animals; Aorta, Thoracic; Chronic Disease; Cyclosporine; Drug Therapy, Combination; Graft Rejection; | 1994 |
Leflunomide: an active antiinflammatory and antiproliferative agent in models of dermatologic disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bromodeoxyuridine; Cell Division; Chronic Disease; | 1995 |
Histological characterization and pharmacological control of chronic rejection in xenogeneic and allogeneic heart transplantation.
Topics: Animals; Chronic Disease; Cricetinae; Cyclosporine; Disease Models, Animal; Graft Rejection; Heart T | 1998 |